IL2 and Alzheimer disease: Treg expansion through peripheral IL‐2/IL‐2 monoclonal antibody complexes or adoptive transfer upon ex vivo activation has rendered positive results in mouse models of ALS and AD such as SOD1G93A mice (Sheean et al., 2018), 5xFAD‐Rag2Ko mice (Faridar et al., 2022), 3xTg‐AD mice (Baek et al., 2016) and APP/PS1 mice (Dansokho et al., 2016).